PMID- 30709957
OWN - NLM
STAT- MEDLINE
DCOM- 20200921
LR  - 20200921
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 46
IP  - 7
DP  - 2019 Jul
TI  - Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish 
      Population with Psoriatic Arthritis.
PG  - 710-715
LID - 10.3899/jrheum.180460 [doi]
AB  - OBJECTIVE: To examine the grade of agreement between very low disease activity 
      (VLDA) and Disease Activity Index for Psoriatic Arthritis (DAPSA) remission, as 
      well as their association with the effect of the disease as assessed by the 
      Psoriatic Arthritis Impact of Disease (PsAID) questionnaire in patients with 
      psoriatic arthritis in routine clinical practice. METHODS: Posthoc analysis of 
      data from a cross-sectional multicenter study. Patients were included who 
      fulfilled the Classification for Psoriatic Arthritis (CASPAR) criteria with at 
      least 1 year of disease duration and were treated with biological and/or 
      conventional synthetic disease-modifying antirheumatic drugs according to routine 
      clinical practice in Spain. Patients were considered in VLDA if they met 7/7 of 
      the minimal disease activity criteria. DAPSA and clinical (c)DAPSA score </= 4 
      identified remissions. RESULTS: Of the 227 patients included in the original 
      study, 26 (11.5%), 52 (22.9%), and 65 (28.6%) were in VLDA, DAPSA remission, and 
      cDAPSA remission, respectively. There was a moderate agreement between VLDA and 
      DAPSA remission (kappa = 0.52) or cDAPSA remission (kappa = 0.42). Patients with VLDA had 
      less effect of the disease as measured by PsAID [mean total score (SD): VLDA 1.1 
      (1.2); DAPSA remission 1.3 (1.5); cDAPSA remission 1.7 (1.6)]. There was a 
      moderate agreement between DAPSA remission or cDAPSA remission and PsAID < 4 (kappa = 
      0.46 and kappa = 0.58 respectively), while poor agreement (kappa = 0.18) was found 
      between VLDA and PsAID < 4. CONCLUSION: VLDA criteria seem to be more stringent 
      for assessing a status of remission; however, DAPSA remission shows better 
      correlation with a patient-acceptable symptoms state than VLDA does.
FAU - Queiro, Ruben
AU  - Queiro R
AUID- ORCID: 0000-0002-8418-7145
FAU - Canete, Juan D
AU  - Canete JD
FAU - Montilla, Carlos
AU  - Montilla C
FAU - Abad, Miguel Angel
AU  - Abad MA
FAU - Montoro, Maria
AU  - Montoro M
FAU - Gomez, Susana
AU  - Gomez S
FAU - Cabez, Ana
AU  - Cabez A
CN  - MAAPS Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20190201
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
CIN - J Rheumatol. 2019 Jul;46(7):663-664. PMID: 31262750
EIN - J Rheumatol. 2019 Sep;46(9):1252. PMID: 31474615
MH  - Adult
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/blood/*drug therapy/*epidemiology/pathology
MH  - C-Reactive Protein/analysis
MH  - Cross-Sectional Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Remission Induction
MH  - Retrospective Studies
MH  - *Severity of Illness Index
MH  - Spain/epidemiology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
OTO - NOTNLM
OT  - DISEASE ACTIVITY
OT  - DISEASE ACTIVITY CRITERIA
OT  - PSORIATIC ARTHRITIS
OT  - REMISSION
EDAT- 2019/02/03 06:00
MHDA- 2020/09/22 06:00
CRDT- 2019/02/03 06:00
PHST- 2018/10/16 00:00 [accepted]
PHST- 2019/02/03 06:00 [pubmed]
PHST- 2020/09/22 06:00 [medline]
PHST- 2019/02/03 06:00 [entrez]
AID - jrheum.180460 [pii]
AID - 10.3899/jrheum.180460 [doi]
PST - ppublish
SO  - J Rheumatol. 2019 Jul;46(7):710-715. doi: 10.3899/jrheum.180460. Epub 2019 Feb 1.